PROVECTUS BIOPHARMACEUTICALS, INC. Retained Earnings (Accumulated Deficit)
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$265.13M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$264.14M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$262.85M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$261.69M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$265.13M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$264.14M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$262.85M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$261.69M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$260.38M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$258.56M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$257.42M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$255.06M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$254.04M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$253.19M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$252.69M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$252.03M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$251.25M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$250.42M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$249.59M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$248.86M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$248.14M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$247.06M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$246.03M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$244.80M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$243.74M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$242.16M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$240.49M 10-K · filed 2022-03-29 |
| 2020-09-30 | -$238.82M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$237.26M 10-Q · filed 2020-08-12 |
| 2020-03-31 | -$235.64M 10-Q · filed 2020-05-13 |
| 2019-12-31 | -$233.82M 10-K · filed 2021-03-02 |
| 2019-09-30 | -$232.26M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$230.44M 10-Q · filed 2019-08-08 |
| 2019-03-31 | -$228.26M 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$226.89M 10-K · filed 2020-03-05 |
| 2018-09-30 | -$224.71M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$223.10M 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$221.64M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$218.74M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$216.02M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$212.91M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$209.61M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$205.22M 10-K · filed 2018-03-23 |
| 2016-09-30 | -$200.22M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$194.35M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$189.30M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$180.80M 10-K · filed 2017-03-31 |
| 2015-09-30 | -$171.14M 10-Q · filed 2015-11-05 |
| 2015-06-30 | -$165.36M 10-Q · filed 2015-08-06 |
| 2015-03-31 | -$160.82M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$156.29M 10-K · filed 2016-03-30 |
| 2014-09-30 | -$157.11M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$153.36M 10-Q · filed 2014-08-07 |
| 2014-03-31 | -$152.72M 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$146.05M 10-K · filed 2015-03-12 |
| 2013-09-30 | -$129.45M 10-Q · filed 2013-11-12 |
| 2013-06-30 | -$124.90M 10-Q · filed 2013-08-08 |
| 2013-03-31 | -$122.52M 10-Q · filed 2013-05-10 |
| 2012-12-31 | -$118.35M 10-K · filed 2014-03-13 |
| 2012-09-30 | -$116.43M 10-Q · filed 2012-11-08 |
| 2012-06-30 | -$114.08M 10-Q · filed 2012-08-08 |
| 2012-03-31 | -$110.25M 10-Q · filed 2012-05-09 |
| 2011-12-31 | -$105.78M 10-K · filed 2013-03-14 |
| 2011-09-30 | -$102.33M 10-Q · filed 2011-11-08 |
| 2011-06-30 | -$95.89M 10-Q · filed 2011-08-09 |
| 2010-12-31 | -$86.35M 10-K · filed 2012-03-14 |